Skip to content

Effectiveness of Etoricoxib as an Additive Analgesic to Epidural Analgesia in Colon or Rectal Fast-track Surgery

A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Effectiveness of Etoricoxib as an Additive Analgesic to Epidural Analgesia in Colon or Rectal Fast-track Surgery

Status
Terminated
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01259830
Enrollment
81
Registered
2010-12-14
Start date
2011-03-31
Completion date
2014-04-30
Last updated
2014-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-operative Pain

Keywords

fast-track, colon or rectal surgery, pain relief

Brief summary

Post-operative pain after laparoscopic colon and rectal surgery in fast-track design. A fast-track program is an evidence-based, multimodal approach for patients undergoing surgery to reduce perioperative morbidity, hospital stay and cost and to increase patient centered well-being. Optimized pain relief is a core component of any fast-track regimen. In this context epidural analgesia has become the standard of care for early postoperative pain therapy. However, it is debated whether non-opioid analgesics should be given as adjuncts when epidural analgesia is already present. The purpose of this study is to demonstrate that the administration of etoricoxib 120mg additionally to the clinical routine therapy (epidural catheter) reduces the post-operative pain level during movement after laparoscopic colon surgery in the fast-track design.

Detailed description

A fast-track program is an evidence-based, multimodal approach for patients undergoing surgery to reduce perioperative morbidity, hospital stay and cost and to increase patient centered well-being. Particularly in visceral surgery of the colon it is gaining widespread acceptance (Schwenk 2009). Optimized pain relief is a core component of any fast-track regimen (Kehlet and Wilmore 2008). In this context epidural analgesia has become the standard of care for early postoperative pain therapy (Hasenberg 2009), providing superior pain relief compared to parenteral opioids (Block 2001). However, it is debated whether non-opioid analgesics should be given as adjuncts when epidural analgesia is already present. Some studies have found reduced pain using NSAID as adjunct (Scott 1994), leading to a positive recommendation in the German guidelines for postoperative pain therapy (S3-Leitlinie). However, other studies (Mogensen 1992) have not found an effect of non-opioids in addition to epidural analgesia. Further studies are also needed to assess whether nonopioid adjuncts can facilitate the change from epidural to systemic analgesia (typically on the 2nd or 3rd postoperative day) and reduce opioid consumption during the days after catheter removal. Fast-track surgery is a multi-model process, and every step in this process needs to be fine-tuned to yield best results (Langelotz 2005). Until now studies have compared only groups with either epidural or systemic analgesia, but for optimal recovery a sequential approach with a combination of both is probably a better choice. A typical multimodal analgesia regimen after removal of an epidural at our institution consists of acetaminophen and ibuprofen. Opioids are avoided if possible, but are added if needed. An improved non-opioid analgesia regimen is a sought-after goal in this fast-track-phase. The study is controlled in terms of the type of surgery (laparoscopic colon and rectal surgery) and all factors of the multimodal analgesia treatment.

Interventions

DRUGArcoxia®120 mg

Arcoxia® over encapsulated 120 mg; Perioperatively 6 days 1 tablet (Arcoxia® 120 mg) for oral use

DRUGP Tablet White Lichtenstein

P Tablet White Lichtenstein over encapsulated; Perioperatively 6 days 1 tablet for oral use

Sponsors

Claudia Spies
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* aged 18 or over * written informed consent * no inclusion in other medical studies according to the AMG (German drug law) during the study period * realization of colon or rectal surgery in the fast track design after clinical standards including an epidural catheter

Exclusion criteria

* ASA status IV-V * allergy against etoricoxib, other components or other NSAID * coronary heart disease * heart insufficiency NYHA II-IV * cerebrovascular disease * peripheral arterial occlusive disease * untreated arterial hypertonus * active peptic ulcera or active gastrointestinal bleeding * minor to severe liver dysfunction (beginning from Child - Plugh - Classification A) * kidney insufficiency * inflammatory bowel disease * pregnancy (positive hCG laboratory test) or lactation * Women of child-bearing potential who are not using a highly effective contraception method with a pearl-index \< 1 during study participation and for at least 3 consecutive months after study inclusion. * placement in an institution on order of an official authority * missing consent for saving and passing on pseudonymous data * hereditary galactose-intolerance, lactase deficit, glucose-galactose-malabsorption * no correct epidural catheter placement within 48 h after surgery

Design outcomes

Primary

MeasureTime frameDescription
Primary end point of the study is the average pain level (scale 0-10) in the area of surgery during movement (walking a fixed number of steps) under active epidural analgesia, at the third day following laparoscopic colon or rectal surgery.Third postoperative dayTo demonstrate that the administration of etoricoxib 120mg additionally to the clinical routine therapy (epidural catheter) reduces the post-operative pain level during movement at the third day after laparoscopic colon or rectal surgery in the fast-track design.

Secondary

MeasureTime frameDescription
Post-operative pain level during rest in the first 2 days after laparoscopic colon or rectal surgery.In the first 2 days after laparoscopic colon or rectal surgery
Post-operative pain level during rest and movement from the third (one day after epidural catheter removal) until the fifth day after laparoscopic colon or rectal surgeryIn the first three days after epidural catheter removal
Incidence of pain events and the average pain intensity in body parts outside of the area of operations.In the first three days after epidural catheter removal
Incidence of new organ dysfunctionsIn the first nine days after laparoscopic colon or rectal surgeryOrgan dysfunctions (cardiovascular, gastrointestinal, renal, respiratory, cognitive, infective)
Post-operative pain level during movement in the first 2 days after laparoscopic colon or rectal surgery.In the first 2 days after laparoscopic colon or rectal surgery
Patients level of satisfactionIn the first five days after laparoscopic colon or rectal surgery
Incidence of side effectsIn the first nine days after laparoscopic colon or rectal surgerySide effects by IMP
Postoperative intensive care unit stayPeriod of intensive care unit stay, an exspected average of one day
Amount and frequency of intake of rescue medicationIn the first five days after laparoscopic colon or rectal surgery
Postoperative LOSPeriod of hospital stay, an exspected average of seven days

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026